Outcome of all 16 patients with del 17p− at registration (intent-to-treat)
UPN . | Age/sex . | FISH karyotype . | PA refractory . | Donor . | Status at SCT . | SCT (regimen) . | Outcome . |
---|---|---|---|---|---|---|---|
005004 | 63/M | del 17p− | Yes | SIB | SD | Yes (FC) | REL +3, died of PD +19 |
005008 | 56/M | del 17p− | Yes | NA (UD) | SD | Yes (FBC) | Alive in CR, 46+ mo (MRD− 46+) |
011002 | 39/M | del 17p−; del 13q− | No | PMUD | NA | Yes (FC) | REL +3, died of PD +10 |
012005 | 58/M | del 17p−; del 13q−; del 11q− | Yes | MMUD | PR2 | Yes (FBC) | Alive in CR, 43+ mo (MRD− 43+) |
012007 | 58/F | del 17p−; +12; t(14;?) | Yes | PMUD | PR3 | Yes (FC) | Alive in CR, 38+ mo (MRD− 38+) |
012008 | 56/M | del 17p− | No | WMUD | PR5 | Yes (FC) | Alive in CR, 39+ mo (MRD− 39+)* |
013001 | 54/F | del 17p− | Untested | PMUD | PR1 | Yes (FC) | Alive in CR, 59+ mo (MRD− 54+) |
019002 | 38/F | del 17p− | Untested | NA (UD) | PR3 | Yes (TCD) | REL +21, died of PD +22 |
026001 | 49/M | del 17p− | Yes | NA | NA | No | Died of PD (Richter transformation) +6 mo after registration without being transplanted |
033003 | 48/F | del 17p−; del 13q− | Yes | PMUD | PR3 | Yes (TCD) | Died of TRM +10 |
041008 | 62/M | del 17p− | Yes | NA | NA | No | Died of PD (Richter transformation) +9 mo after registration without being transplanted |
125012 | 62/F | del 17p− | Yes | SIB | SD | Yes | REL +3; alive 37+ mo |
125014 | 58/M | del 17p−; del 13q− | No | WMUD | PR5 | Yes (FBC) | Alive in CR, 18+ mo |
144005 | 51/F | del 17p−; del 11q− | Yes | PMUD | SD | Yes (FBC) | Alive in CR, 75+ mo (MRD− 59+) |
144011 | 44/F | del 17p− | Yes | Not found | NA | No | Died of PD +17 mo after registration (no donor) |
144010 | 43/M | del 17p−; del 6q− | Untested | SIB | PR2 | Yes (FC) | REL +11, died of PD +24 mo |
UPN . | Age/sex . | FISH karyotype . | PA refractory . | Donor . | Status at SCT . | SCT (regimen) . | Outcome . |
---|---|---|---|---|---|---|---|
005004 | 63/M | del 17p− | Yes | SIB | SD | Yes (FC) | REL +3, died of PD +19 |
005008 | 56/M | del 17p− | Yes | NA (UD) | SD | Yes (FBC) | Alive in CR, 46+ mo (MRD− 46+) |
011002 | 39/M | del 17p−; del 13q− | No | PMUD | NA | Yes (FC) | REL +3, died of PD +10 |
012005 | 58/M | del 17p−; del 13q−; del 11q− | Yes | MMUD | PR2 | Yes (FBC) | Alive in CR, 43+ mo (MRD− 43+) |
012007 | 58/F | del 17p−; +12; t(14;?) | Yes | PMUD | PR3 | Yes (FC) | Alive in CR, 38+ mo (MRD− 38+) |
012008 | 56/M | del 17p− | No | WMUD | PR5 | Yes (FC) | Alive in CR, 39+ mo (MRD− 39+)* |
013001 | 54/F | del 17p− | Untested | PMUD | PR1 | Yes (FC) | Alive in CR, 59+ mo (MRD− 54+) |
019002 | 38/F | del 17p− | Untested | NA (UD) | PR3 | Yes (TCD) | REL +21, died of PD +22 |
026001 | 49/M | del 17p− | Yes | NA | NA | No | Died of PD (Richter transformation) +6 mo after registration without being transplanted |
033003 | 48/F | del 17p−; del 13q− | Yes | PMUD | PR3 | Yes (TCD) | Died of TRM +10 |
041008 | 62/M | del 17p− | Yes | NA | NA | No | Died of PD (Richter transformation) +9 mo after registration without being transplanted |
125012 | 62/F | del 17p− | Yes | SIB | SD | Yes | REL +3; alive 37+ mo |
125014 | 58/M | del 17p−; del 13q− | No | WMUD | PR5 | Yes (FBC) | Alive in CR, 18+ mo |
144005 | 51/F | del 17p−; del 11q− | Yes | PMUD | SD | Yes (FBC) | Alive in CR, 75+ mo (MRD− 59+) |
144011 | 44/F | del 17p− | Yes | Not found | NA | No | Died of PD +17 mo after registration (no donor) |
144010 | 43/M | del 17p−; del 6q− | Untested | SIB | PR2 | Yes (FC) | REL +11, died of PD +24 mo |
CR indicates complete remission; F, female; FBC, FC + busulfan; FC, fludarabine-cyclophosphamide; FISH, fluorescence in situ hybridization; M, male; MMUD, mismatched unrelated donor; −, negative minimal residual disease; NA, not available; PA, purine analogue; PD, progressive disease; PMUD, partially matched unrelated donor; PR, partial remission; REL, relapse; SCT, stem cell transplantation; SIB, 10/ of 10 allele-matched sibling; TCD, FC + total body irradiation 2Gy + in vivo alemtuzumab; andWMUD, well-matched unrelated donor.
This patient was diagnosed with a diffuse large cell lymphoma (DLCL) 9 months after transplant, which was counted as event in the event-free survival analysis. Although a formal proof of clonal identity with the CLL by sequencing was not performed, the fact that paraffin slides of the DLCL were MRD negative with the CLL-specific primers and that the patient became a durably MRD-negative complete donor chimera at the time of DLCL occurrence suggest that DLCL and CLL were not clonally related.